Q1 2025 Jazz Pharmaceuticals PLC Earnings Call Transcript
Key Points
- Jazz Pharmaceuticals PLC (JAZZ) reported strong commercial performance with total revenues of $898 million, driven by growth in its neuroscience portfolio, particularly Zywav and Epidiolex.
- Zywav experienced a 9% year-over-year growth, maintaining its position as the number one branded treatment for narcolepsy and the only FDA-approved therapy for idiopathic hypersomnia.
- Epidiolex revenues increased by 10% year-over-year, with expectations to reach blockbuster status in 2025.
- The company made significant progress in its R&D pipeline, including the submission of a supplemental new drug application for Zepzelca and a positive CHMP opinion for Zanidatamab in Europe.
- The acquisition of Chimerix has strengthened Jazz Pharmaceuticals PLC (JAZZ)'s presence in rare oncology, adding Dordaviprone to its pipeline, which is seen as a meaningful and durable revenue opportunity.
- Jazz Pharmaceuticals PLC (JAZZ) faced near-term headwinds with certain oncology products, impacting overall oncology portfolio performance.
- Rylaze's net product sales decreased by 8% year-over-year, affected by changes in pediatric treatment protocols for acute lymphoblastic leukemia.
- The company incurred a $172 million charge related to Xyrem antitrust litigation settlements, impacting adjusted net income and earnings per share.
- There was a decline in oncology product revenues due to one fewer shipping week in the first quarter of 2025 compared to the previous year.
- Potential tariffs and their impact on the supply chain remain a concern, although Jazz Pharmaceuticals PLC (JAZZ) has taken steps to mitigate this risk.
Hello and thank you for standing by. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to the Jazz Pharmaceuticals first-quarter 2025 webcast conference call. (Operator Instructions)
Thank you. I would now like to turn the call over to Executive Director of Investor Relations, Jeff Macdonald. Please go ahead.
Thank you, operator, and good afternoon, everyone. Today, Jazz Pharmaceuticals reported its first quarter of 2025 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors should also refer to the press release we issued earlier today that is available on our website.
On the call today are Bruce Cozadd, Chairman and Chief Executive Officer; Renee Gala, President and Chief Operating Officer; Rob Iannone, Executive Vice President, Global Head of R&D and Chief Medical Officer; and Phil Johnson, Chief Financial Officer.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
